×

Human Exportin-5 (XPO5) ELISA Kit

  • Cat.No.: AE11002HU

  • Reactivity: Human (Homo sapiens)

To Purchase AE11002HU

Size:
48T 96T
Price: Inquire

Reagent Preparation







Results demonstration







Assay Procedure Summary







Certificate



Product Details

Species Reactivity Human (Homo sapiens)
UniProt Q9HAV4
Abbreviation XPO5
Alternative Names RP3-337H4.5; FLJ14239; FLJ32057; FLJ45606; KIAA1291;
Range 0.312-20 ng/mL
Sensitivity 0.115 ng/mL
Sample Type Serum, Plasma, Other biological fluids
Detection Method Sandwich
Analysis Method Quantitive
Assay Duration 1-4.5h
Sample Volume 1-200 μL
Detection Wavelengt 450 nm

Test principle

This assay employs a two-site sandwich ELISA to quantitate XPO5 in samples. An antibody specific for XPO5 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any XPO5 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for XPO5 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of XPO5 bound in the initial step. The color development is stopped and the intensity of the color is measured.
 

Product Overview

Exportin-5 belongs to a large family of karyopherins that mediate the transport of proteins and other cargo between the nuclear and cytoplasmic compartments. The deduced 1,205-amino acid protein has a calculated molecular mass of about 136 kD. XPO5 and XPO1 share 25% amino acid identity. Northern blot analysis detected transcripts of about 3.6 and 5.0 kb in all tissues examined.XPO5 bound the nucleoporins NUP214 and NUP153 in a RAN-GTP-independent manner and bound a cargo protein, ILF3, in a RAN-GTP-dependent manner. XPO5 bound ILF3 at its double-stranded RNA-binding domain (dsRBD) and also bound the dsRBDs of other proteins. XPO5 directly interacted with VA1 RNA in a RAN-GTP-dependent manner.
 

Components


Reagents

Quantity

Reagents

Quantity

Assay plate (96 Wells)

1

Instruction manual

1

Standard (lyophilized)

2

Sample Diluent

1 x 20 mL

Biotin-Conjugate (concentrate 100 x)

1 x 120 μL

Biotin-Conjugate Diluent

1 x 12 mL

Streptavidin-HRP  (concentrate 100 x)

1 x 120 μL

Streptavidin-HRP Diluent   

1 x 12 mL

Wash Buffer (concentrate 25 x)

1 x 20 mL

Substrate Solution

1 x 10 mL

Stop Solution

1 x 6 mL

Adhesive Films

4

 

Specificity

This assay has high sensitivity and excellent specificity for detection of Human XPO5. No significant cross-reactivity or interference between Human XPO5 and analogues was observed.
 

Recovery

Matrices listed below were spiked with certain level of recombinant Human XPO5 and the recovery rates were calculated by comparing the measured value to the expected amount of Human XPO5 in samples.

Sample Type

Number

Recovery range (%)

Average(%)

Serum

10

90-101

96

EDTA plasma

10

89-97

93

Heparin plasma

10

91-99

95

 

Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision. Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in forty separate assays to assess inter-assay precision. CV (%) = SD/meanX100 Intra-Assay: CV<8% Inter-Assay: CV<12%
 

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Human XPO5 and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample Type

1:2

1:4

1:8

1:16

Serum

78-89%

81-99%

92-103%

95-105%

EDTA plasma

91-101%

90-98%

93-101%

91-98%

Heparin plasma

92-103%

93-102%

92-99%

91-101%

 

Stability

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37°C for 4 and 7 days, and compare O.D.values of the kit kept at 37°C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37°C can be considered as 6 months at 2 - 8°C, which means 7 days at 37°C equaling 12 months at 2 - 8°C).
 

Sample collection and storage

Serum: Use a serum separator tube (SST) and allow samples to clot for two hours at room temperature or overnight at 2 - 8°C before centrifugation for 15 minutes at 1000 × g. Remove serum and assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles. Plasma: Collect plasma using EDTA, or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 × g at 2 - 8°C within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles. Other biological fluids: Centrifuge samples for 20 minutes at 1000 × g. Remove particulates and assay immediately or store samples in aliquot at -20°C or -80°C. Avoid repeated freeze/thaw cycles.
 

Kits storage instructions

Store at 2-8°C. Please refer to Instruction Manual.
 
  1. AGO2 protein: A Key Enzyme in the miRNA Pathway as a Diagnostic and 3 Prognostic Biomarker in Adrenocortical Carcinoma IF: 4.100
    Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy characterised by diagnostic challenges, high recurrence rates, and poor prognosis. This study explored the role microRNA (miRNA) processing genes in ACC, and their potential role as diagnostic and prognostic biomarkers.
  2. AGO2 protein: A Key Enzyme in the miRNA Pathway as a Diagnostic and 3 Prognostic Biomarker in Adrenocortical Carcinoma IF: preprint
    Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy. Current treatment algorithms are associated with diagnostic limitations, high recurrence rates and poor prognosis. Identifying specific biomarkers that facilitate accurate diagnosis and provide prognostic insights could significantly enhance the patient outcomes in ACC.